Scandinavian ChemoTech AB (publ) (CMOTEC-B.ST)
SEK 1.33
(-3.62%)
SEK 1.33
(-3.62%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -19.57 Million SEK | 2.47% |
| 2022 | -20.8 Million SEK | -25.6% |
| 2021 | -17.02 Million SEK | -60.12% |
| 2020 | -10.77 Million SEK | 13.08% |
| 2019 | -12.01 Million SEK | -186.92% |
| 2018 | -8.03 Million SEK | 53.87% |
| 2017 | -7.72 Million SEK | -1.16% |
| 2016 | -7.64 Million SEK | -565.6% |
| 2015 | -1.14 Million SEK | -4035.89% |
| 2014 | -27.78 Thousand SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -3.24 Million SEK | -41.94% |
| 2024 Q1 | -2.29 Million SEK | 50.54% |
| 2023 Q2 | -5.24 Million SEK | -25.12% |
| 2023 Q4 | -4.79 Million SEK | -44.35% |
| 2023 FY | - SEK | 2.47% |
| 2023 Q1 | -4.19 Million SEK | 18.59% |
| 2023 Q3 | -3.31 Million SEK | 36.72% |
| 2022 Q2 | -5 Million SEK | -36.25% |
| 2022 FY | - SEK | -25.6% |
| 2022 Q4 | -5.14 Million SEK | -26.45% |
| 2022 Q3 | -4.07 Million SEK | 18.66% |
| 2022 Q1 | -3.67 Million SEK | 18.12% |
| 2021 FY | - SEK | -60.12% |
| 2021 Q1 | -2.14 Million SEK | 0.37% |
| 2021 Q2 | -3.29 Million SEK | -53.52% |
| 2021 Q3 | -4.32 Million SEK | -31.13% |
| 2021 Q4 | -4.48 Million SEK | -3.82% |
| 2020 Q2 | -1.93 Million SEK | 27.14% |
| 2020 FY | - SEK | 13.08% |
| 2020 Q3 | -2.16 Million SEK | -12.28% |
| 2020 Q1 | -2.64 Million SEK | 27.33% |
| 2020 Q4 | -2.15 Million SEK | 0.55% |
| 2019 FY | - SEK | -186.92% |
| 2019 Q2 | -1.75 Million SEK | 25.13% |
| 2019 Q4 | -3.64 Million SEK | -34.55% |
| 2019 Q1 | -2.34 Million SEK | -275.92% |
| 2019 Q3 | -2.7 Million SEK | -54.62% |
| 2018 Q3 | -548.11 Thousand SEK | 58.48% |
| 2018 FY | - SEK | 53.87% |
| 2018 Q4 | -622.46 Thousand SEK | -13.57% |
| 2018 Q2 | -1.31 Million SEK | -22.4% |
| 2018 Q1 | -1.07 Million SEK | 0.0% |
| 2017 Q1 | -2.23 Million SEK | 1.45% |
| 2017 FY | - SEK | -1.16% |
| 2017 Q3 | -2.12 Million SEK | 11.94% |
| 2017 Q2 | -2.41 Million SEK | -7.66% |
| 2016 Q1 | -244.57 Thousand SEK | 33.12% |
| 2016 FY | - SEK | -565.6% |
| 2016 Q4 | -2.27 Million SEK | -202.99% |
| 2016 Q2 | -442.13 Thousand SEK | -80.78% |
| 2016 Q3 | -749.67 Thousand SEK | -69.56% |
| 2015 Q4 | -365.66 Thousand SEK | -7658.71% |
| 2015 Q3 | -4713.00 SEK | 0.0% |
| 2015 FY | - SEK | -4035.89% |
| 2014 FY | - SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Simris Alg AB (publ) | -22.36 Million SEK | 12.449% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 93.833% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 93.058% |
| Xintela AB (publ) | -53.47 Million SEK | 63.384% |
| Active Biotech AB (publ) | -43.88 Million SEK | 55.388% |
| Amniotics AB (publ) | -27.14 Million SEK | 27.867% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | -37.715% |
| BioArctic AB (publ) | 275.38 Million SEK | 107.11% |
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 94.677% |
| Camurus AB (publ) | 562.54 Million SEK | 103.48% |
| Cantargia AB (publ) | -284.31 Million SEK | 93.114% |
| CombiGene AB (publ) | -35.33 Million SEK | 44.592% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 86.099% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | -14.601% |
| Genovis AB (publ.) | 64.57 Million SEK | 130.321% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 82.961% |
| Mendus AB (publ) | -97.84 Million SEK | 79.99% |
| Isofol Medical AB (publ) | -37.02 Million SEK | 47.118% |
| Intervacc AB (publ) | -68.98 Million SEK | 71.616% |
| Kancera AB (publ) | -61.88 Million SEK | 68.364% |
| Karolinska Development AB (publ) | -26.78 Million SEK | 26.898% |
| LIDDS AB (publ) | -39.67 Million SEK | 50.645% |
| Lipum AB (publ) | -37.11 Million SEK | 47.253% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -61.756% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 162.346% |
| NextCell Pharma AB | -40.98 Million SEK | 52.229% |
| OncoZenge AB (publ) | 7.26 Million SEK | 369.461% |
| Saniona AB (publ) | -69.69 Million SEK | 71.908% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 88.47% |
| Ziccum AB (publ) | -20.34 Million SEK | 3.751% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 979050.0% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 91.76% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -841.298% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | -45.775% |
| Corline Biomedical AB | -1.69 Million SEK | -1057.836% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 88.704% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | 64.276% |
| Aptahem AB (publ) | -10 Million SEK | -95.61% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 269.53% |
| Fluicell AB (publ) | -25.91 Million SEK | 24.446% |
| Biovica International AB (publ) | -119.5 Million SEK | 83.617% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 53.631% |
| AcouSort AB (publ) | -16.7 Million SEK | -17.218% |
| Abliva AB (publ) | -93.6 Million SEK | 79.084% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 93.864% |
| 2cureX AB (publ) | -35.13 Million SEK | 44.277% |
| I-Tech AB | 30.34 Million SEK | 164.521% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 97.26% |
| Cyxone AB (publ) | -20.41 Million SEK | 4.09% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 80.89% |
| Biosergen AB | 228 Thousand SEK | 8687.281% |
| Nanologica AB (publ) | -62.11 Million SEK | 68.481% |
| SynAct Pharma AB | -222.7 Million SEK | 91.208% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | 55.361% |
| BioInvent International AB (publ) | -312.7 Million SEK | 93.739% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 6427.788% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 46717.777% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 91.547% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -122.174% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | 81.964% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -70.712% |